RESEARCH AREA

Multiple Sclerosis

In the past few decades the MS field has witnessed a rapid expansion of new therapies. CNO has been involved for the past 25 years in the development of most of the new therapies for MS. CNO continues to contribute to the field and remains at the forefront of MS clinical research.

RESEARCH AREA

MS

There are currently several studies for Multiple Sclerosis taking place at the clinic. Please contact the coordinators of these studies, Victorine Sikati Foko or Chantal Paquette for more information.

Clinical Trials Active

These clinical trials are currently open and accepting participants. For more information contact information is listed below

These studies are underway, they/we are no longer enrolling new participants.

These clinical trials have concluded.

EFC17504 FREVIVA (Sanofi- Aventis)

Secondary progressive MS population
For more information contact Chantal Paquette at chantal.paquette@neuro-outaouais.ca

EFC17919 FREXALT (Sanofi-Aventis)

Relapsing remitting MS population
For more information contact Chantal Paquette at chantal.paquette@neuro-outaouais.ca

rTMS in\n Multiple Sclerosis

Non Invasive Neuromodulation in MS induced Spastic Paraparesis (the Villeneuve study)
For more information contact Chantal Paquette at chantal.paquette@neuro-outaouais.ca

Clinical Trial Presently Ongoing

MN43964 OLERO (Hoffman-LaRoche)

Chantal Paquette Recruitment is closed

GN41791 FENtrepide (Hoffmann-La Roche)

Victorine Sikati Foko Recruitment is closed

LTS17043 (Sanofi-Aventis)

Chantal Paquette Recruitment is closed

PASS OBS13434 (Genzyme - Sanofi)

Victorine Sikati Foko Recruitment is closed

LTS17261 (Sanofi-Aventis)

Victorine Sikati Foko Recruitment is closed

Publications:

View Publication

Sclérose en plaques

In the past few decades the MS field has witnessed a rapid expansion of new therapies. CNO has been involved for the past 25 years in the development of most of the new therapies for MS. CNO continues to contribute to the field and remains at the forefront of MS clinical research.

Principale cause de handicap neurologique chez les jeunes adultes en Amérique du Nord.

Maladie auto-immune, chez des personnes génétiquement prédisposées, déclenchée par un facteur environnemental.

Participer

Essais cliniques

Recrutement en cours

Étude : FREVIVA (EFC17504 )

Population cible : SEP secondairement progressive, 18 à 60 ans.

Pour plus d’information, contactez Chantal Paquette à chantal.paquette@neuro-outaouais.ca

Étude : FREXALT (EFC17919 )

Population cible : SEP rémittente-récurrente, 18 à 55 ans.

Pour plus d’information, contactez Chantal Paquette à chantal.paquette@neuro-outaouais.ca

Étude : Neuromodulation non invasive dans la paraparésie spastique induite par la SEP (étude CeV)

Population cible : atteinte de la marche liée à la SEP, 18 à 70 ans.

Pour plus d’information, contactez Ibrahim Sangare à ibrahim.sangare@neuro-outaouais.ca

Clinical Evaluation

At CNO, we have a bilingual, multidisciplinary team consisting of neurologists, physiotherapists, medical assistants, specialized nurses and office administrators. Our team is experienced in the diagnosis, treatment and follow-up of patients with MS. Investigations and monitoring evaluations often include MRI, evoked potentials, blood tests and cerebrospinal fluid (CSF) analysis which can all be done at or arranged through the clinic. Initial consultations are available by referral from a physician.

Treatment

The treatment armamentarium used in MS has grown exponentially over the past few decades and continues to grow. To support physicians, CNO developed a repository of up-to-date information on the various MS treatments.

Many treatments in MS are administered intravenously. These can be received at CNO’s infusion clinic, administered by specialized MS nurses and supervised by experienced neurologists.

While treatments in MS have changed the clinical evolution of the disease, they are not a cure. Much remains to be accomplished to fully understand the mechanisms of the disease, how to stop the progression of neurological disability and enable repair within the central nervous system (CNS).

CNO continues to be active in the field of clinical research in MS. Clinical trials at CNO are seen as a viable treatment option for patients whose disease does not respond optimally to currently available treatments.

rTMS in MS

Repetitive transcranial magnetic stimulation (rTMS) is a form of non-invasive neuromodulation. It is a method by which we can modulate how neuronal networks communicate within and across neuronal networks. It consists of inducing brief, repetitive, focal, small electrical currents in the brain using an electromagnet. It is commonly used to treat medication resistant depression. While  it is still regarded as experimental, our experience with rTMS has convinced us that it can help alleviate a number of MS related symptoms such as weakness, spasticity, pain and neurogenic bladder. We are currently involved in clinical trials looking at rTMS in patients with MS.

Rehabilitation

Exercise is important for patients with multiple sclerosis (MS) to optimize mobility, support recovery from relapses, reduce pain and spasticity, and improve balance. However, exercise is often not a realistic option for individuals with MS without the help of experts and access to specialized equipment.

Through its partnership with Clinique NeuroGym, CNO offers patients with MS the opportunity to access physiotherapy services within the clinic. Clinique NeuroGym specializes in motor-enabling rehabilitation for individuals with a range of neurological conditions, including MS.

Together, CNO and Clinique Neurogym have conducted research projects in the field of MS rehabilitation and continue to collaborate to improve clinical outcomes of patients with MS.

Clinical Trials

Recruiting

Study: FREVIVA (EFC17504 )

Target population: secondary progressive MS population aged 18-60 For more information contact Chantal Paquette at chantal.paquette@neuro-outaouais.ca

Study: FREXALT (EFC17919 )

Target population: relapsing remitting MS population aged 18-55 For more information contact Chantal Paquette at chantal.paquette@neuro-outaouais.ca

Study: Non Invasive Neuromodulation in MS induced Spastic Paraparesis (CEV study)

Target population: MS induced walking impairment population aged 18-70

For more information contact Ibrahim Sangare at ibrahim.sangare@neuro-outaouais.ca

En cours

Étude: OLERO (MN43964)

Chantal Paquette – Recrutement terminé

Étude: FENtrepide (GN41791)

Victorine Sikati Foko – Recrutement terminé

Étude: LTS17043

Chantal Paquette – Recrutement terminé

Étude: PASS OBS13434

Victorine Sikati Foko – Recrutement terminé

Étude: LTS17261

Victorine Sikati Foko – Recrutement terminé

Terminés

2022: Étude ACT16753 (Phase II)
2017: Étude ENSEMBLE (Phase III)
2021: Étude ACT16877 (Phase II)
2017: Étude ASCLEPIOS (Phase III)
2021: Étude LIBERTO (Phase IIIb/IV)
2020: Étude GN41971 (Phase III)
2020: Étude HERCULES (Phase III)
2019: Étude ALITHIOS (Phase IIIb)
2019: Étude DRI BTK (Phase II)
2019: Étude NOVA (Phase III)
2018: Étude AFFINITY (Phase II)
2016: Étude EVOLVE (Phase III)
2016: Étude CHORDS (Phase IIIb)
2015: Étude TOPAZ (Phase IIIb)

2014: Étude INFORMS extension (Phase III)
2013: Étude SYNERGY (Phase II)
2013: Étude REsuMeS (Phase II)
2012: Étude MOBILE (Phase II)
2011: Étude OPERA (Phase III)
2011: Étude ASCEND (Phase III)
2011: Étude DreaMS extension (Phase II)
2011: Étude TERACLES (Phase III)
2011: Étude CARE-MS extension (Phase III)
2011: Étude INFORMS (Phase III)
2010: Étude DECIDE (Phase III)
2010: Étude SURPASS (Phase III)
2010: Étude CBAF312A2201 ext. (Phase II)
2010: Étude DreaMS (Phase II)

2009: Étude LTS6050 (Phase III) 2009: Étude CBAF312A2201 (Phase II) 2009: Étude TOWER (Phase III) 2009: Étude LTS6047 (Phase II) 2009: Étude C32322 (Phase II) 2009: Étude CARE-MS-I (Phase III) 2009: Étude CARE-MS-II (Phase III) 2008: Étude PDY6045 (Phase II) 2007: Étude STRATA extension (Phase III) 2007: Étude TIME (Phase II) 2007: Étude BEYOND follow-up (Phase IIIb) 2007: Étude DEFINE (Phase III) 2007: Étude CLARITY extension (Phase III) 2007: Étude EFC6049 (Phase III)

2007: Étude EFC6049 (Phase III)
2006: Étude STRATA (Phase III)
2005: Étude OLYMPUS (Phase II-III)
2005: Étude HERMES (Phase II)
2005: Étude CHOICE (Phase II)
2005: Étude CLARITY (Phase III)
2004: Étude AFFIRM extension (Phase III)
2004: Étude BEYOND (Phase IIIb)
2003: Étude GLANCE (Phase II)
2002: Étude AFFIRM (Phase III)

Publications

Cognitive Evolution in Tysabri (natalizumab)-Treated Multiple Sclerosis Patients (P4.171)

Prolonged-release Fampridine as adjunct therapy to active enabled motor training in Multiple Sclerosis patients: A pilot, double-blind, placebo-controlled study (P1.123)

Natalizumab, First Therapy to Demonstrate a Significant Impact on Multiple Sclerosis Disease Severity (P6.180)

Treatment Sequencing and Satisfaction With Alemtuzumab in Relapsing Multiple Sclerosis Patients: Interim Results of the Real-world PRO-ACT Study (P3.2-097)

Single Digit Modality: What is a Clinically Significant Change in Multiple Sclerosis Patients (880)
Publication